Projects per year
Abstract
This study evaluated the hypothesis that 68Ga-PSMA-11 PET SUV, obtained via an advanced DL approach, correlates better with MR ADC maps than values from conventional PET-MR. Additionally, we aimed to identify the optimal SUV threshold for maximum correlation with ADC values. A cohort of 32 prostate cancer patients underwent CT and corresponding PET-MR imaging. The dataset underwent K-fold cross-validation, dividing it into four folds. In each fold, 24 patients were used for training, and 8 for validation to create DL models. ADC maps from 27 out of 32 patients were successfully aligned with T2 images for detailed analysis, revealing an inverse correlation (ρ = −0.20 to −0.51) between ADC and SUV values in prostate cancer zones. Statistically significant differences in mean SUV values were observed between PETMRI and PETDL. DL-based SUV values show a stronger correlation with ADC than conventional PET-MR values in our investigation.
| Original language | English |
|---|---|
| Article number | 905 |
| Number of pages | 13 |
| Journal | International Journal of Molecular Sciences |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2025 |
Keywords
- apparent diffusion coefficient
- attenuation correction
- deep learning
- prostate cancer
- prostate-specific membrane antigen
- simultaneous PET/MR
- standardized uptake values
Access to Document
Other files and links
Projects
- 2 Finished
-
Integrative brain imaging technologies
Egan, G. (Primary Chief Investigator (PCI)), Jamadar, S. (Chief Investigator (CI)), Chen, Z. (Chief Investigator (CI)), Premaratne, M. (Chief Investigator (CI)), Fornito, A. (Chief Investigator (CI)) & Shah, J. (Partner Investigator (PI))
17/01/19 → 31/12/22
Project: Research
-
ARC Centre of Excellence for Integrative Brain Function
Egan, G. (Primary Chief Investigator (PCI)), Rosa, M. (Chief Investigator (CI)), Lowery, A. (Chief Investigator (CI)), Stuart, G. (Chief Investigator (CI)), Arabzadeh, E. (Chief Investigator (CI)), Skafidas, E. (Chief Investigator (CI)), Ibbotson, M. (Chief Investigator (CI)), Petrou, S. (Chief Investigator (CI)), Paxinos, G. (Chief Investigator (CI)), Mattingley, J. (Chief Investigator (CI)), Garrido, M. (Chief Investigator (CI)), Sah, P. K. (Chief Investigator (CI)), Robinson, P. A. (Chief Investigator (CI)), Martin, P. (Chief Investigator (CI)), Grunert, U. (Chief Investigator (CI)), Tanaka, K. (Partner Investigator (PI)), Mitra, P. (Partner Investigator (PI)), Johnson, G. (Partner Investigator (PI)), Diamond, M. (Partner Investigator (PI)), Margrie, T. (Partner Investigator (PI)), Leopold, D. (Partner Investigator (PI)), Movshon, J. (Partner Investigator (PI)), Markram, H. (Partner Investigator (PI)), Victor, J. (Partner Investigator (PI)), Hill, S. (Partner Investigator (PI)) & Jirsa, V. K. (Partner Investigator (PI))
Australian National University (ANU), Eidgenössische Technische Hochschule Zürich (ETH Zürich) (Federal Institute of Technology Zurich), Australian Research Council (ARC), Karolinska Institutet (Karolinska Institute), Council of the Queensland Institute of Medical Research (trading as QIMR Berghofer Medical Research Institute), Ecole Polytechnique Federale de Lausanne (EPFL) (Swiss Federal Institute of Technology in Lausanne) , Monash University, University of Melbourne, University of New South Wales (UNSW), University of Queensland , University of Sydney, Monash University – Internal University Contribution, NIH - National Institutes of Health (United States of America), Cornell University, New York University, Francis Crick Institute, Scuola Internazionale Superiore di Studi Avanzati (International School for Advanced Studies), Duke University, Cold Spring Harbor Laboratory, RIKEN
25/06/14 → 31/12/21
Project: Research